General Announcement::Share Repurchase Report (From November 1, 2021 to November 30, 2021)

[Cover]
[Document Filed]	Share Repurchase Report
[Applicable Law]	Article 24-6, paragraph 1 of the Financial Instruments and Exchange Act of Japan
[Filed with]	Director, Kanto Local Finance Bureau
[Filing Date]	December 14, 2021
[Reporting period]	From November 1, 2021 to November 30, 2021
[Company Name]	Takeda Pharmaceutical Company Limited
[Title and Name of Representative]	Christophe Weber, Representative Director, President & Chief Executive Officer
[Address of Head Office]	1-1, Doshomachi 4-chome,Chuo-ku, Osaka
	(The above address is the registered head office location and the ordinary business
	operations are conducted at the "Nearest Place of Contact")
[Telephone Number]	Not applicable
[Name of Contact Person]	Not applicable
[Nearest Place of Contact]	1-1,Nihonbashi-Honcho2-chome,Chuo-ku, Tokyo
	(Global Headquarters)
[Telephone Number]	[phone] (Main telephone number)
[Name of Contact Person]	Norimasa Takeda, Chief Accounting Officer & Corporate Controller, Global Finance
[Place for public inspection]	Takeda Pharmaceutical Company Limited (Global Headquarters)
	(1-1, Nihonbashi Honcho 2-chome,Chuo-ku, Tokyo)
	Tokyo Stock Exchange, Inc.
	(2-1, Nihonbashi Kabutocho, Chuo-ku, Tokyo)
	Nagoya Stock Exchange, Inc.
	(8-20, Sakae 3-chome,Naka-ku, Nagoya)
	Fukuoka Stock Exchange
	(14-2, Tenjin 2-chome,Chuo-ku, Fukuoka)
	Sapporo Stock Exchange
	(14-1, Minamiichijonishi 5-chome,Chuo-ku, Sapporo)

Class of Shares: Common Stock

1. Status of repurchase

1. Status of repurchase pursuant to a resolution approved by a General Meeting of Shareholders Not applicable
2. Status of repurchase pursuant to a resolution approved by a meeting of the Board of Directors

		As of November 30, 2021
	Number of Shares (shares)	Total Repurchase
	Amount (JPY)
Status of the resolution of the Board of
Directors (October 28, 2021)
(Period of repurchase: from November 2, 2021
to April 29, 2022)		35,000,000	100,000,000,000
Repurchases during this reporting month (Date	(Date)
of repurchase)	November 5, 2021	1,646,500	5,357,628,100
	November 8, 2021	1,646,500	5,374,574,700
	November 9, 2021	1,646,500	5,338,392,500
	November 10, 2021	1,215,400	3,939,670,400
	November 11, 2021	1,215,400	3,966,769,200
	November 12, 2021	1,215,400	3,941,806,800
	November 15, 2021	1,215,400	3,951,473,100
	November 16, 2021	1,215,400	3,998,587,700
	November 17, 2021	1,134,500	3,748,740,400
	November 18, 2021	1,134,500	3,719,876,300
	November 19, 2021	1,134,500	3,677,053,200
	November 22, 2021	915,700	2,965,369,700
Total	ー	15,335,700	49,979,942,100
Aggregate shares repurchased as of the end of
this reporting month		15,335,700	49,979,942,100
Progress of share repurchase (%)		43.82	49.98

(Note) The period of repurchase is listed on a trade date basis and the repurchase of shares is listed on a delivery date basis.

2.	Status of disposition
	Not applicable
3.	Status of treasury shares held
		As of November 30, 2021
	Status of treasury shares held
	as of the end of the reporting month	Number of Shares (shares)
Total number of issued shares	1,582,252,525
Number of treasury shares held	15,511,118

(Notes) 1. The number of treasury shares held includes shares purchased on a demand for purchase made by shareholders holding shares less than one unit.

2. The number of treasury shares held does not include the shares held by the ESOP trust account and the shares held by the BIP trust account.